Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Modifiable factors affecting older patients' quality of life and physical function during cancer treatment.

Kirkhus L, Harneshaug M, Šaltytė Benth J, Grønberg BH, Rostoft S, Bergh S, Hjermstad MJ, Selbæk G, Wyller TB, Kirkevold Ø, Borza T, Saltvedt I, Jordhøy MS.

J Geriatr Oncol. 2019 Aug 20. pii: S1879-4068(19)30144-4. doi: 10.1016/j.jgo.2019.08.001. [Epub ahead of print]

2.

Autocrine activin A signalling in ovarian cancer cells regulates secretion of interleukin 6, autophagy, and cachexia.

Pettersen K, Andersen S, van der Veen A, Nonstad U, Hatakeyama S, Lambert C, Lach-Trifilieff E, Moestue S, Kim J, Grønberg BH, Schilb A, Jacobi C, Bjørkøy G.

J Cachexia Sarcopenia Muscle. 2019 Aug 21. doi: 10.1002/jcsm.12489. [Epub ahead of print]

3.

Associations between severe co-morbidity and muscle measures in advanced non-small cell lung cancer patients.

Grønberg BH, Valan CD, Halvorsen T, Sjøblom B, Jordhøy MS.

J Cachexia Sarcopenia Muscle. 2019 Aug 6. doi: 10.1002/jcsm.12469. [Epub ahead of print]

4.

Frailty identified by geriatric assessment is associated with poor functioning, high symptom burden and increased risk of physical decline in older cancer patients: Prospective observational study.

Kirkhus L, Šaltytė Benth J, Grønberg BH, Hjermstad MJ, Rostoft S, Harneshaug M, Selbæk G, Wyller TB, Jordhøy MS.

Palliat Med. 2019 Mar;33(3):312-322. doi: 10.1177/0269216319825972. Epub 2019 Feb 4. No abstract available.

5.

A comparison of CT based measures of skeletal muscle mass and density from the Th4 and L3 levels in patients with advanced non-small-cell lung cancer.

Grønberg BH, Sjøblom B, Wentzel-Larsen T, Baracos VE, Hjermstad MJ, Aass N, Bremnes RM, Fløtten Ø, Bye A, Jordhøy M.

Eur J Clin Nutr. 2019 Jul;73(7):1069-1076. doi: 10.1038/s41430-018-0325-5. Epub 2018 Sep 25.

PMID:
30254241
6.

Associations between hematologic toxicity and health-related quality of life during first-line chemotherapy in advanced non-small-cell lung cancer: a pooled analysis of two randomized trials.

Kristensen A, Solheim TS, Fløtten Ø, Grønberg BH.

Acta Oncol. 2018 Nov;57(11):1574-1579. doi: 10.1080/0284186X.2018.1492151. Epub 2018 Aug 3.

PMID:
30074418
7.

Screening for frailty among older patients with cancer using blood biomarkers of inflammation.

Harneshaug M, Kirkhus L, Benth JŠ, Grønberg BH, Bergh S, Whist JE, Rostoft S, Jordhøy MS.

J Geriatr Oncol. 2019 Mar;10(2):272-278. doi: 10.1016/j.jgo.2018.07.003. Epub 2018 Jul 23.

PMID:
30049582
8.

Substantial nation-wide improvement in lung cancer relative survival in Norway from 2000 to 2016.

Brustugun OT, Grønberg BH, Fjellbirkeland L, Helbekkmo N, Aanerud M, Grimsrud TK, Helland Å, Møller B, Nilssen Y, Strand TE, Solberg SK.

Lung Cancer. 2018 Aug;122:138-145. doi: 10.1016/j.lungcan.2018.06.003. Epub 2018 Jun 6.

PMID:
30032822
9.

Cancer patients' knowledge about their disease and treatment before, during and after treatment: a prospective, longitudinal study.

Berger O, Grønberg BH, Loge JH, Kaasa S, Sand K.

BMC Cancer. 2018 Apr 3;18(1):381. doi: 10.1186/s12885-018-4164-5.

10.

Expression of Estrogen Receptor-α and Survival in Advanced-stage Non-small Cell Lung Cancer.

Lund-Iversen M, Scott H, Strøm EH, Theiss N, Brustugun OT, Grønberg BH.

Anticancer Res. 2018 Apr;38(4):2261-2269.

PMID:
29599348
11.

Survival in Limited Disease Small Cell Lung Cancer According to N3 Lymph Node Involvement.

Valan CD, Slagsvold JE, Halvorsen TO, Herje M, Bremnes RM, Brunsvig PF, Brustugun OT, Fløtten Ø, Levin N, Sundstrøm SH, Grønberg BH.

Anticancer Res. 2018 Feb;38(2):871-876.

PMID:
29374714
12.

Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial.

Malmström A, Poulsen HS, Grønberg BH, Stragliotto G, Hansen S, Asklund T, Holmlund B, Łysiak M, Dowsett J, Kristensen BW, Söderkvist P, Rosell J, Henriksson R; Nordic Clinical Brain Tumor Study Group (NCBTSG).

Acta Oncol. 2017 Dec;56(12):1776-1785. doi: 10.1080/0284186X.2017.1332780. Epub 2017 Jul 4.

PMID:
28675067
13.

Geriatric assessment is superior to oncologists' clinical judgement in identifying frailty.

Kirkhus L, Šaltytė Benth J, Rostoft S, Grønberg BH, Hjermstad MJ, Selbæk G, Wyller TB, Harneshaug M, Jordhøy MS.

Br J Cancer. 2017 Aug 8;117(4):470-477. doi: 10.1038/bjc.2017.202. Epub 2017 Jun 29.

14.

Cancer cachexia associates with a systemic autophagy-inducing activity mimicked by cancer cell-derived IL-6 trans-signaling.

Pettersen K, Andersen S, Degen S, Tadini V, Grosjean J, Hatakeyama S, Tesfahun AN, Moestue S, Kim J, Nonstad U, Romundstad PR, Skorpen F, Sørhaug S, Amundsen T, Grønberg BH, Strasser F, Stephens N, Hoem D, Molven A, Kaasa S, Fearon K, Jacobi C, Bjørkøy G.

Sci Rep. 2017 May 17;7(1):2046. doi: 10.1038/s41598-017-02088-2.

15.

Muscle mass and association to quality of life in non-small cell lung cancer patients.

Bye A, Sjøblom B, Wentzel-Larsen T, Grønberg BH, Baracos VE, Hjermstad MJ, Aass N, Bremnes RM, Fløtten Ø, Jordhøy M.

J Cachexia Sarcopenia Muscle. 2017 Oct;8(5):759-767. doi: 10.1002/jcsm.12206. Epub 2017 May 10.

16.

Corrigendum to "Prognosis in advanced lung cancer - A prospective study examining key clinicopathological factors" [Lung Cancer 88 (2015) 304-309].

Simmons CP, Koinis F, Fallon MT, Fearon KC, Bowden J, Solheim TS, Gronberg BH, McMillan DC, Gioulbasanis I, Laird BJ.

Lung Cancer. 2017 Jun;108:256. doi: 10.1016/j.lungcan.2017.04.015. Epub 2017 Apr 28. No abstract available.

17.

Measurement of health-related quality of life during chemotherapy - the importance of timing.

Kristensen A, Solheim TS, Amundsen T, Hjelde HH, Kaasa S, Sørhaug S, Grønberg BH.

Acta Oncol. 2017 May;56(5):737-745. doi: 10.1080/0284186X.2017.1279748. Epub 2017 Jan 24.

PMID:
28117614
18.

Medical complexity and time to lung cancer treatment - a three-year retrospective chart review.

Stokstad T, Sørhaug S, Amundsen T, Grønberg BH.

BMC Health Serv Res. 2017 Jan 17;17(1):45. doi: 10.1186/s12913-016-1952-y.

19.

Tumour size reduction after the first chemotherapy-course and outcomes of chemoradiotherapy in limited disease small-cell lung cancer.

Halvorsen TO, Herje M, Levin N, Bremnes RM, Brustugun OT, Fløtten Ø, Kaasa S, Sundstrøm S, Grønberg BH.

Lung Cancer. 2016 Dec;102:9-14. doi: 10.1016/j.lungcan.2016.10.003. Epub 2016 Oct 15.

PMID:
27987595
20.

Drug Dose Per Kilogram Lean Body Mass Predicts Hematologic Toxicity From Carboplatin-Doublet Chemotherapy in Advanced Non-Small-Cell Lung Cancer.

Sjøblom B, Benth JŠ, Grønberg BH, Baracos VE, Sawyer MB, Fløtten Ø, Hjermstad MJ, Aass N, Jordhøy M.

Clin Lung Cancer. 2017 Mar;18(2):e129-e136. doi: 10.1016/j.cllc.2016.09.008. Epub 2016 Oct 5.

PMID:
27825639
21.

Comorbidity and outcomes of concurrent chemo- and radiotherapy in limited disease small cell lung cancer.

Halvorsen TO, Sundstrøm S, Fløtten Ø, Brustugun OT, Brunsvig P, Aasebø U, Bremnes RM, Kaasa S, Grønberg BH.

Acta Oncol. 2016 Nov;55(11):1349-1354. Epub 2016 Aug 23.

PMID:
27549509
22.

Skeletal muscle radiodensity is prognostic for survival in patients with advanced non-small cell lung cancer.

Sjøblom B, Grønberg BH, Wentzel-Larsen T, Baracos VE, Hjermstad MJ, Aass N, Bremnes RM, Fløtten Ø, Bye A, Jordhøy M.

Clin Nutr. 2016 Dec;35(6):1386-1393. doi: 10.1016/j.clnu.2016.03.010. Epub 2016 Apr 1.

PMID:
27102408
23.

Does chemotherapy improve health-related quality of life in advanced pancreatic cancer? A systematic review.

Kristensen A, Vagnildhaug OM, Grønberg BH, Kaasa S, Laird B, Solheim TS.

Crit Rev Oncol Hematol. 2016 Mar;99:286-98. doi: 10.1016/j.critrevonc.2016.01.006. Epub 2016 Jan 15. Review.

PMID:
26819138
24.

Comparing comorbidity scales: Attending physician score versus the Cumulative Illness Rating Scale for Geriatrics.

Kirkhus L, Jordhøy M, Šaltytė Benth J, Rostoft S, Selbæk G, Jensen Hjermstad M, Grønberg BH.

J Geriatr Oncol. 2016 Mar;7(2):90-8. doi: 10.1016/j.jgo.2015.12.003. Epub 2015 Dec 28.

PMID:
26739557
25.

Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancer.

Donnem T, Kilvaer TK, Andersen S, Richardsen E, Paulsen EE, Hald SM, Al-Saad S, Brustugun OT, Helland A, Lund-Iversen M, Solberg S, Gronberg BH, Wahl SG, Helgeland L, Fløtten O, Pohl M, Al-Shibli K, Sandanger TM, Pezzella F, Busund LT, Bremnes RM.

Ann Oncol. 2016 Feb;27(2):225-32. doi: 10.1093/annonc/mdv560. Epub 2015 Nov 16. Review.

PMID:
26578726
26.

Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer.

Grønberg BH, Halvorsen TO, Fløtten Ø, Brustugun OT, Brunsvig PF, Aasebø U, Bremnes RM, Tollåli T, Hornslien K, Aksnessæther BY, Liaaen ED, Sundstrøm S; Norwegian Lung Cancer Study Group.

Acta Oncol. 2016 May;55(5):591-7. doi: 10.3109/0284186X.2015.1092584. Epub 2015 Oct 23.

PMID:
26494411
27.

Low muscle mass is associated with chemotherapy-induced haematological toxicity in advanced non-small cell lung cancer.

Sjøblom B, Grønberg BH, Benth JŠ, Baracos VE, Fløtten Ø, Hjermstad MJ, Aass N, Jordhøy M.

Lung Cancer. 2015 Oct;90(1):85-91. doi: 10.1016/j.lungcan.2015.07.001. Epub 2015 Jul 9.

PMID:
26198373
28.

Prognosis in advanced lung cancer--A prospective study examining key clinicopathological factors.

Simmons CP, Koinis F, Fallon MT, Fearon KC, Bowden J, Solheim TS, Gronberg BH, McMillan DC, Gioulbasanis I, Laird BJ.

Lung Cancer. 2015 Jun;88(3):304-9. doi: 10.1016/j.lungcan.2015.03.020. Epub 2015 Mar 28. Erratum in: Lung Cancer. 2017 Jun;108:256.

29.

[Occupational lung cancer in Sør-Trøndelag county].

Slåstad S, Leira HL, Aas O, Amundsen T, Sørhaug S, Sundstrøm S, Grønberg BH, Hilt B.

Tidsskr Nor Laegeforen. 2014 Oct 28;134(20):1943-7. doi: 10.4045/tidsskr.13.0900. eCollection 2014 Oct 28. Norwegian.

30.

Changes in skeletal muscle mass during palliative chemotherapy in patients with advanced lung cancer.

Stene GB, Helbostad JL, Amundsen T, Sørhaug S, Hjelde H, Kaasa S, Grønberg BH.

Acta Oncol. 2015 Mar;54(3):340-8. doi: 10.3109/0284186X.2014.953259. Epub 2014 Sep 16.

PMID:
25225010
31.

Characterization of patients receiving palliative chemo- and radiotherapy during end of life at a regional cancer center in Norway.

Anshushaug M, Gynnild MA, Kaasa S, Kvikstad A, Grønberg BH.

Acta Oncol. 2015 Mar;54(3):395-402. doi: 10.3109/0284186X.2014.948061. Epub 2014 Aug 27.

PMID:
25162953
32.
33.

A placebo-controlled, randomized phase II study of maintenance enzastaurin following whole brain radiation therapy in the treatment of brain metastases from lung cancer.

Grønberg BH, Ciuleanu T, Fløtten Ø, Knuuttila A, Abel E, Langer SW, Krejcy K, Liepa AM, Munoz M, Hahka-Kemppinen M, Sundstrøm S.

Lung Cancer. 2012 Oct;78(1):63-9. doi: 10.1016/j.lungcan.2012.07.007. Epub 2012 Aug 20.

PMID:
22917813
34.

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.

Malmström A, Grønberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, Abacioglu U, Tavelin B, Lhermitte B, Hegi ME, Rosell J, Henriksson R; Nordic Clinical Brain Tumour Study Group (NCBTSG).

Lancet Oncol. 2012 Sep;13(9):916-26. Epub 2012 Aug 8.

PMID:
22877848
35.

Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group.

Fløtten Ø, Grønberg BH, Bremnes R, Amundsen T, Sundstrøm S, Rolke H, Hornslien K, Wentzel-Larsen T, Aasebø U, von Plessen C.

Br J Cancer. 2012 Jul 24;107(3):442-7. doi: 10.1038/bjc.2012.284. Epub 2012 Jul 3.

36.

[Mutation testing for non-small-cell lung cancer].

Brustugun OT, Helland Å, Fjellbirkeland L, Kleinberg L, Ariansen S, Jebsen P, Scott H, Dønnem T, Bremnes R, Berg T, Grønberg BH, Dai HY, Wahl SG, Mangseth K, Helgeland L.

Tidsskr Nor Laegeforen. 2012 Apr 30;132(8):952-5. doi: 10.4045/tidsskr.11.1017. Norwegian.

37.

Prolonged survival in patients with lung cancer with diabetes mellitus.

Hatlen P, Grønberg BH, Langhammer A, Carlsen SM, Amundsen T.

J Thorac Oncol. 2011 Nov;6(11):1810-7. doi: 10.1097/JTO.0b013e31822a75be.

38.

Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy.

Grønberg BH, Sundstrøm S, Kaasa S, Bremnes RM, Fløtten O, Amundsen T, Hjelde HH, Plessen Cv, Jordhøy M.

Eur J Cancer. 2010 Aug;46(12):2225-34. doi: 10.1016/j.ejca.2010.04.009. Epub 2010 May 12.

PMID:
20471248
39.

Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer.

Grønberg BH, Bremnes RM, Fløtten O, Amundsen T, Brunsvig PF, Hjelde HH, Kaasa S, von Plessen C, Stornes F, Tollåli T, Wammer F, Aasebø U, Sundstrøm S.

J Clin Oncol. 2009 Jul 1;27(19):3217-24. doi: 10.1200/JCO.2008.20.9114. Epub 2009 May 11.

PMID:
19433683
40.

The length of consent documents in oncological trials is doubled in twenty years.

Berger O, Grønberg BH, Sand K, Kaasa S, Loge JH.

Ann Oncol. 2009 Feb;20(2):379-85. doi: 10.1093/annonc/mdn623. Epub 2008 Oct 15.

PMID:
18922881
41.

Lung cancer patients' perceptions of informed consent documents.

Sand K, Loge JH, Berger O, Grønberg BH, Kaasa S.

Patient Educ Couns. 2008 Nov;73(2):313-7. doi: 10.1016/j.pec.2008.06.011.

PMID:
18691845
42.

A prospective phase II study: high-dose pemetrexed as second-line chemotherapy in small-cell lung cancer.

Grønberg BH, Bremnes RM, Aasebø U, Brunsvig P, Fløtten O, Amundsen T, von Plessen C, Wang M, Sundstrøm S; Norwegian Lung Cancer Study Group.

Lung Cancer. 2009 Jan;63(1):88-93. doi: 10.1016/j.lungcan.2008.04.003. Epub 2008 Jun 6.

PMID:
18538889
43.

[Investigation in suspected pulmonary tumor].

Kaasa S, Grønberg BH.

Tidsskr Nor Laegeforen. 2005 Nov 3;125(21):2958. Norwegian. No abstract available.

PMID:
16299883
44.

Prognostic significance of Ki-67/MIB-1 proliferation index in meningiomas.

Torp SH, Lindboe CF, Grønberg BH, Lydersen S, Sundstrøm S.

Clin Neuropathol. 2005 Jul-Aug;24(4):170-4.

PMID:
16033133
45.

[The chemical working environment among car painters in Bergen].

Grønberg BH, Moen BE, Bruun T, Dale K, Damås JK, Hovland A, Lunøe E, Stanislaus J, Young S, Hollund BE.

Tidsskr Nor Laegeforen. 1994 Aug 20;114(19):2272-5. Norwegian.

PMID:
7992296

Supplemental Content

Loading ...
Support Center